The institution’s decision was based on the results of a prospective study that took place over a period of 15 years. | Read More
Despite some concerns in the field that immunotherapy might replace image-guided therapy, William Rilling, MD, sees an opportunity for collaboration and additional opportunities for interventional oncology to flourish. | Read More
Researchers assessed whether use of dedicated tumor feeding vessel detection software in embolizing HCC may lead to better local tumor response without an accompanying increase in radiation dose. | Read More
This prospective study evaluated the efficacy and safety of sorafenib therapy within 3 weeks after a second TACE treatment was performed due to recurrence within 6 months of the first TACE treatment for unresectable HCC. | Read More
In this study, researchers assessed whether stereotactic radiofrequency ablation is a safe and minimally invasive alternative when liver resection is not possible. | Read More

Spotlight

Despite some concerns in the field that immunotherapy might replace image-guided therapy, William Rilling, MD, sees an opportunity for collaboration and additional opportunities for interventional oncology to flourish.
The landscape for renal ablation is changing as new studies suggest that certain patients may have outcomes comparable to surgery. Matthew Callstrom, MD, PhD, explains the data underlying this shift and offers advice on preparing to treat more patients with ablation.
Sean Tutton, MD, FSIR, reviews recent research in musculoskeletal interventions, discusses his own practice, and provides advice for colleagues who may want to offer more of these procedures.